Characterization of factor xiii-γ/γ fibrinogen complexesd

David Farrell, M. G. Fried, L. A. Falls

Research output: Contribution to journalArticle

Abstract

About 10% of human plasma fibrinogen is a heterodimer of the composition (a/J')(afl?). The two different 3' chains, 3' and 3', arise from alternative mRNA processing. The 7' chain contains a 20-amino acid extension at the C-terminus that replaces a 4-residue sequence in the 3' chain. Siebenlist, Meh. and Mosesson (Biochemistry 35:10448-10453 (1996)) have shown that the ' chain, but not the 3'A chain, binds to the b subunit of factor XIII. Our results show that fibrin clots made from 3/3' fibrinogen are resistant to fibrinolysis, but only if factor XIII is present during clotting. This suggests that the binding of factor XIII to 3' chains stabilizes clots, possibly by concentrating tile factor XIII at the surface of the growing fibrin matrix. We have therefore investigated the binding interactions of factor XIII and 3/3' fibrinogen. Sedimentation equilibrium analysis indicates that 2 3'/7' fibrinogen molecules can bind to each molecule of factor XIII, but that 3'/3' fibrinogen containing only - chains does not form detectable complexes. These results suggest the involvement of the C-terminal extension of the 3'' chain in binding factor XlII. GamierRobson analysis predicts that the C-terminal 20 residues of 3' fold into an a helix; helical wheel projections of this structure indicate that seven negativelycharged residues, including two tyrosine O-sulfates are clustered on one face of the helix. We propose that these residues mediate the interaction of i/, fibrinogen with factor XIII. Supported by funds from the A.It.A., PA Affiliate (to D.H.F. and M.G.F.) and the W.W. Smith Charitable Trust (to D.tt.F.).

Original languageEnglish (US)
JournalFASEB Journal
Volume11
Issue number9
StatePublished - 1997
Externally publishedYes

Fingerprint

Factor XIII
fibrinogen
Fibrinogen
fibrin
Fibrin
fibrinolysis
Plasma (human)
tiles
concentrating
Biochemistry
wheels
Molecules
biochemistry
Fibrinolysis
Financial Management
Tile
tyrosine
Sedimentation
sulfates
Wheels

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Characterization of factor xiii-γ/γ fibrinogen complexesd. / Farrell, David; Fried, M. G.; Falls, L. A.

In: FASEB Journal, Vol. 11, No. 9, 1997.

Research output: Contribution to journalArticle

Farrell, David ; Fried, M. G. ; Falls, L. A. / Characterization of factor xiii-γ/γ fibrinogen complexesd. In: FASEB Journal. 1997 ; Vol. 11, No. 9.
@article{f01ee755b630432b9857417b560e9274,
title = "Characterization of factor xiii-γ/γ fibrinogen complexesd",
abstract = "About 10{\%} of human plasma fibrinogen is a heterodimer of the composition (a/J')(afl?). The two different 3' chains, 3' and 3', arise from alternative mRNA processing. The 7' chain contains a 20-amino acid extension at the C-terminus that replaces a 4-residue sequence in the 3' chain. Siebenlist, Meh. and Mosesson (Biochemistry 35:10448-10453 (1996)) have shown that the ' chain, but not the 3'A chain, binds to the b subunit of factor XIII. Our results show that fibrin clots made from 3/3' fibrinogen are resistant to fibrinolysis, but only if factor XIII is present during clotting. This suggests that the binding of factor XIII to 3' chains stabilizes clots, possibly by concentrating tile factor XIII at the surface of the growing fibrin matrix. We have therefore investigated the binding interactions of factor XIII and 3/3' fibrinogen. Sedimentation equilibrium analysis indicates that 2 3'/7' fibrinogen molecules can bind to each molecule of factor XIII, but that 3'/3' fibrinogen containing only - chains does not form detectable complexes. These results suggest the involvement of the C-terminal extension of the 3'' chain in binding factor XlII. GamierRobson analysis predicts that the C-terminal 20 residues of 3' fold into an a helix; helical wheel projections of this structure indicate that seven negativelycharged residues, including two tyrosine O-sulfates are clustered on one face of the helix. We propose that these residues mediate the interaction of i/, fibrinogen with factor XIII. Supported by funds from the A.It.A., PA Affiliate (to D.H.F. and M.G.F.) and the W.W. Smith Charitable Trust (to D.tt.F.).",
author = "David Farrell and Fried, {M. G.} and Falls, {L. A.}",
year = "1997",
language = "English (US)",
volume = "11",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "9",

}

TY - JOUR

T1 - Characterization of factor xiii-γ/γ fibrinogen complexesd

AU - Farrell, David

AU - Fried, M. G.

AU - Falls, L. A.

PY - 1997

Y1 - 1997

N2 - About 10% of human plasma fibrinogen is a heterodimer of the composition (a/J')(afl?). The two different 3' chains, 3' and 3', arise from alternative mRNA processing. The 7' chain contains a 20-amino acid extension at the C-terminus that replaces a 4-residue sequence in the 3' chain. Siebenlist, Meh. and Mosesson (Biochemistry 35:10448-10453 (1996)) have shown that the ' chain, but not the 3'A chain, binds to the b subunit of factor XIII. Our results show that fibrin clots made from 3/3' fibrinogen are resistant to fibrinolysis, but only if factor XIII is present during clotting. This suggests that the binding of factor XIII to 3' chains stabilizes clots, possibly by concentrating tile factor XIII at the surface of the growing fibrin matrix. We have therefore investigated the binding interactions of factor XIII and 3/3' fibrinogen. Sedimentation equilibrium analysis indicates that 2 3'/7' fibrinogen molecules can bind to each molecule of factor XIII, but that 3'/3' fibrinogen containing only - chains does not form detectable complexes. These results suggest the involvement of the C-terminal extension of the 3'' chain in binding factor XlII. GamierRobson analysis predicts that the C-terminal 20 residues of 3' fold into an a helix; helical wheel projections of this structure indicate that seven negativelycharged residues, including two tyrosine O-sulfates are clustered on one face of the helix. We propose that these residues mediate the interaction of i/, fibrinogen with factor XIII. Supported by funds from the A.It.A., PA Affiliate (to D.H.F. and M.G.F.) and the W.W. Smith Charitable Trust (to D.tt.F.).

AB - About 10% of human plasma fibrinogen is a heterodimer of the composition (a/J')(afl?). The two different 3' chains, 3' and 3', arise from alternative mRNA processing. The 7' chain contains a 20-amino acid extension at the C-terminus that replaces a 4-residue sequence in the 3' chain. Siebenlist, Meh. and Mosesson (Biochemistry 35:10448-10453 (1996)) have shown that the ' chain, but not the 3'A chain, binds to the b subunit of factor XIII. Our results show that fibrin clots made from 3/3' fibrinogen are resistant to fibrinolysis, but only if factor XIII is present during clotting. This suggests that the binding of factor XIII to 3' chains stabilizes clots, possibly by concentrating tile factor XIII at the surface of the growing fibrin matrix. We have therefore investigated the binding interactions of factor XIII and 3/3' fibrinogen. Sedimentation equilibrium analysis indicates that 2 3'/7' fibrinogen molecules can bind to each molecule of factor XIII, but that 3'/3' fibrinogen containing only - chains does not form detectable complexes. These results suggest the involvement of the C-terminal extension of the 3'' chain in binding factor XlII. GamierRobson analysis predicts that the C-terminal 20 residues of 3' fold into an a helix; helical wheel projections of this structure indicate that seven negativelycharged residues, including two tyrosine O-sulfates are clustered on one face of the helix. We propose that these residues mediate the interaction of i/, fibrinogen with factor XIII. Supported by funds from the A.It.A., PA Affiliate (to D.H.F. and M.G.F.) and the W.W. Smith Charitable Trust (to D.tt.F.).

UR - http://www.scopus.com/inward/record.url?scp=33750225142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750225142&partnerID=8YFLogxK

M3 - Article

VL - 11

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 9

ER -